Business Wire

CA-ALATION

Share
BARC Study Reveals Top Challenges to Becoming a Data-Driven Enterprise

Alation Inc. , the leader in enterprise data catalogs, today announced the results of a global study, Leverage Your Data, A Data Strategy Checklist for the Journey to the Data-Driven Enterprise , which found that while nearly every company wants to be data-driven, the lack of documentation and knowledge about data inhibits that goal. The study, sponsored by Alation and carried out by Business Application Research Center (BARC) , reveals that a key enabler to becoming a data-driven enterprise is the implementation of a successful data catalog that drives active contribution and collaboration from the business user.

According to the study, 90% of respondents indicate that data has a high priority in enterprise decision-making yet only 25% state that decisions are predominantly or purely made based on data. Several roadblocks inhibit the business user from embracing data and therefore prevent organizations from becoming data-driven. Participants report a lack of information and documentation on data, insight into who is using what data and for what purpose, and inconsistent meanings and interpretations of data as blockers. They also cite that data access is too complicated and that significant time is wasted asking the same questions about data or repeating work, further preventing business users from making data-driven decisions.

To overcome these obstacles, the report says that enterprises need to foster a data culture that empowers the business users. The data catalog drives data democratization by providing widespread access to data and encouraging a collaborative information exchange where data users – from business users to data analysts – can engage in an iterative process that ensures data quality and the proper use of data. The catalog tackles the challenges associated with data documentation by providing a business glossary that facilitates cross-departmental access to approved data definitions, ensuring that the meaning and interpretations of key figures in the organization are consistent. By removing these hurdles and empowering business users with a collaborative platform, organizations are able to unlock the true value of their data. This is why 77% of respondents currently use or are planning to use a data catalog.

“The BARC study mirrors the challenges our customers experienced prior to using Alation. Organizations need a data catalog that enables search and discovery, provides the context on how to use the data, and fosters collaboration among data users,” said Satyen Sangani, CEO and co-founder of Alation. “Alation is the foundation for building a data culture and we’re seeing more enterprises leverage our data catalog to drive that cultural shift and derive more value from their data.”

For four consecutive years, Alation has been named the top-ranked data catalog in Dresner Advisory Services’ 2020 Wisdom of Crowds® Data Catalog Market Study . Alation has also been recognized as a leader in the Forrester Wave for Machine Learning Data Catalogs , a three-time leader in Gartner’s Magic Quadrant for Metadata Management Solutions , and selected as a Gartner Peer Insights Customer’s Choice for Metadata Management Solutions .

To download a copy of Leverage Your Data, a Data Strategy Checklist for the Journey to the Data-Driven Enterprise , click here .

To learn more about the study, register for the BARC Launch Party: How do Companies Find, Understand and use Trusted Data for Analytics? which is being held twice, once at 9am CEST and once at 5pm CEST on June 25, 2020.

To learn how customers use Alation for data governance, register for our upcoming webinar with Bob Seiner, author of Non-Invasive Data Governance , and Alation customer, Riot Games on July 7, 2020.

About Alation

Alation pioneered the data catalog market, leading the evolution of data management towards driving data culture. Alation customers leverage the data catalog as a platform for data search & discovery, data governance, data stewardship, analytics, and digital transformation. With its powerful Behavioral Analysis Engine, inbuilt collaboration capabilities, and open interfaces, Alation provides a platform to support a broad range of data intelligence solutions by combining machine learning with human insight to tackle the most demanding challenges in data management. Nearly 200 organizations are driving their data cultures and improving their organizations’ decision making with Alation, including AbbVie, DraftKings, Exelon, Finnair, Genentech, GoDaddy, Marks & Spencer, MercadoLibre, Munich Re, New Balance, New Relic, Pfizer, Scandinavian Airlines, Scout24 and US Foods. Headquartered in Silicon Valley, Alation is funded by Costanoa Ventures, Data Collective Venture Capital, Icon Ventures, Sapphire Ventures, and Salesforce Ventures. For more information, visit alation.com .

About BARC

BARC (Business Application Research Center) is one of Europe’s leading analyst firms for business software, focusing on the areas of data, business intelligence (BI) and analytics, enterprise content management (ECM) and customer relationship management (CRM). The company was founded in 1999 as a spin-off of the Chair of Business Administration and Information Systems at the Julius-Maximilians-University in Würzburg. Today, BARC combines empirical and theoretical research, technical expertise and practical experience, including a constant exchange with all market participants. For more information, visit: www.barc-research.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye